Patient impact

The Magle Group is committed to improving health for patients around the world by providing innovative healthcare solutions. We are dedicated to empowering patients, increasing their confidence in our products, and supporting healthcare professionals in delivering the best care possible. Through continuous innovation and a focus on patient-centred care, we strive to improve quality of life and contribute to a healthier future for all.

Identifying Unmet Medical Needs

At Magle Group, understanding the unmet medical needs of patients is the foundation of everything we do. We achieve this through research, close collaboration with clinicians, and engagement with key opinion leaders across the medical field. By continually assessing the healthcare landscape and leveraging our partnerships, we are committed to identifying new ways to improve patient outcomes and advance medical science.

Developing Advanced Technologies

Once a promising idea is identified, development begins within our specialized facilities, equipped to take projects from concept to clinic.

  • Degradable Starch Microspheres (DSM): Our DSM technology is used in oncology, pain management, and regenerative medicine to deliver targeted, effective treatments.
  • Dextran: Our versatile dextran-based technology supports drug delivery, wound care, and tissue engineering by enabling safe, adaptable, and sustainable healthcare solutions.
  • Amniotic-Based Stem Cells: With unique regenerative properties, our stem cell technology promotes healing and tissue repair, offering new hope for patients with inflammatory diseases, wounds, and organ damage.

Optimizing Patient Outcome

Before products can reach the market, they undergo rigorous testing and compliance procedures. Magle Group ensures regulatory licenses and approvals are in place. Clinical trials are designed, managed, and supported across different stages. Regulatory documentation is prepared to meet global standards. This step ensures products are both safe and effective, meeting clinical and compliance requirements.

Commitment to Quality

Our aspiration is to always supply high-quality, safe products and services that help to positively impact patient outcomes and improve health economics. We are continuously investing in our operations and staff to ensure our staff are trained and educated in the most important quality standards and requirements to ensure all team members carry out high-quality work.

Continuing Innovation

We continuously invest in research, clinical collaborations, and feedback from practical applications to refine and improve our technologies. Through proactive post-market surveillance, we monitor the safety of our products. By actively gathering user insights and vital data we identify opportunities for improvement. This cycle of continuous learning and development strengthens the evidence base behind our innovative solutions and drives better outcomes for patients.

Driving Better Patient Outcomes

At Magle Group, our aspiration is to deliver innovative solutions that make a meaningful impact on patients’ lives. Through our technologies and patient-centric approach, we have helped improve outcomes and enhance quality of life for thousands worldwide. These numbers reflect the tangible value our products bring to healthcare.

Warfarin sodium

Treating 1 million patients with heart disease

Melperone hydrochloride

Treating 100 000 CNS patients

Isradipine

Treating 50 000 patients with high blood pressure

Case Reports

As EmboCept® S DSM 50 μm is degradable DSM-TACE can be successfully used to treat colorectal liver metastases, permitting multiple treatments.

View study

The use of DSM-TACE offers an effective treatment option for ovarian cancer patients refractory after standard therapy. 

View study

SmartPAN® enabled the surgeon to perform targeted closure with no complications during the follow-up period.

View study